Australia's Monoquant Developing PCR-Based DNA Assay to Monitor CML Patients | GenomeWeb

Monoquant, an Australian company spun out of Flinders University to commercialize molecular methods to monitor minimal residual disease in blood cancers, has developed a PCR-based DNA assay that can routinely detect one cancerous cell in 10 million normal cells in chronic myeloid leukemia patients, according to a company founder.

The company believes that its assay could be a viable alternative to the current standard method of monitoring minimal residual disease by assaying RNA to detect BCR-ABL translocations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.